Kolltan Pharmaceuticals

Kolltan Pharmaceuticals

Based: New Haven, CT
Raised: $25 million
Investors: HBM Partners AG

The scoop: Kolltan has been developing new oncology therapies based on the scientific work of Yale's Joseph Schlessinger, the co-founder of the company. The biotech has kept a low profile generally, but recently wooed Gerald McMahon, the Senior VP of oncology R&D at MedImmune, into the CEO's job. About 30 staffers are at work at the biotech, which has raised a total of some $75 million. Peter Hirth, the CEO at Plexxikon, sits on the board. The biotech is developing monoclonal antibodies that target receptor tyrosine kinases.

Kolltan Pharmaceuticals

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir.

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.